BackPDL Biopharma Overview

PDL Biopharma Receivables

PDL Biopharma's receivables is $6.6M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$6.56M
↓ 91.36% YoYΔ $-69.34M vs prior year quarter

Peer average

Loading

PDL Biopharma Receivables History

Loading

PDL Biopharma vs. peers: Receivables Comparison

Loading

PDL Biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PDL Biopharma (PDLI) FAQ

As of the most recent data (September 2020), PDLI shows a receivables of $6.6M. That compares with $76M in the prior-year period — down 91.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PDLI's receivables is now $6.6M (was $76M) — a 91.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PDL Biopharma is outperforming or lagging.

Tracking PDLI's receivables over time shows whether PDL Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $6.6M That compares with $76M in the prior-year period — down 91.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has PDL Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $6.6M) with ownership activity and broader fundamentals.

PDL Biopharma's receivables is $6.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.